First-Line Antiviral Treatment for Influenza in Adults
For adults with influenza, oseltamivir 75 mg orally twice daily for 5 days is the first-line treatment, initiated as soon as possible regardless of symptom duration in hospitalized patients or those at high risk of complications. 1
Standard Dosing for Adults
Treatment regimen:
- Oseltamivir 75 mg orally twice daily for 5 days 2, 1
- Can be administered without regard to meals, though taking with food may reduce gastrointestinal side effects 2
- Available as capsules (30 mg, 45 mg, 75 mg) or oral suspension (6 mg/mL concentration) 2
Prophylaxis regimen:
- Oseltamivir 75 mg orally once daily 2
- Duration: 7 days after last known exposure (routine); 14+ days if institutional outbreak 2
Renal Impairment Adjustments
The dosing must be adjusted based on creatinine clearance 3, 4:
For treatment (CrCl 10-30 mL/min):
For prophylaxis (CrCl 10-30 mL/min):
- 30 mg once daily for 10 days after exposure, OR
- 75 mg every other day for 10 days (5 total doses) 5
For moderate impairment:
For severe impairment:
No dose adjustment is needed for mild renal impairment or hepatic dysfunction 6.
Pregnancy Considerations
Pregnant women and those within 2 weeks postpartum should receive standard-dose oseltamivir (75 mg twice daily) as they are at high risk for complications 1. The benefits of therapy outweigh potential risks 5. No dose adjustment is required during pregnancy unless renal impairment is present.
Alternative Routes and Agents
When oral administration is not feasible:
Intravenous peramivir:
- Single 600 mg IV infusion over 15-30 minutes 2, 7
- Not approved for prophylaxis 2
- Requires dose adjustment in renal impairment 8
Inhaled zanamivir:
- 10 mg (two 5-mg inhalations) twice daily for 5 days for treatment 2
- 10 mg once daily for prophylaxis 2
- Contraindicated in patients with chronic respiratory diseases (asthma, COPD) due to bronchospasm risk 3, 5
- Must use proprietary "Diskhaler" device; not for nebulizers or ventilators 3
Baloxavir (oral, single-dose option):
- 40 mg single dose for patients 40-80 kg 7
- 80 mg single dose for patients ≥80 kg 7
- Approved for patients ≥12 years 7
Key Clinical Considerations
Who should receive treatment:
- All hospitalized patients with influenza, regardless of illness duration 1
- Outpatients with severe or progressive illness 1
- High-risk patients: chronic medical conditions, immunocompromised, age ≥65 years 1
- Pregnant women and early postpartum period 1
Timing is critical:
- Greatest benefit when started within 48 hours of symptom onset 9, 1
- However, hospitalized or severely ill patients may benefit even if started >48 hours after onset 9
Duration considerations:
- Standard 5-day course for uncomplicated influenza 1
- Consider longer duration for immunocompromised patients or those with severe lower respiratory disease, as viral replication may be prolonged 1
Common Pitfalls to Avoid
- Do not combine neuraminidase inhibitors - use monotherapy only 1
- Do not routinely use higher than approved doses - standard dosing is adequate 1
- Do not withhold treatment pending test results in severely ill or high-risk patients 1
- Do not forget renal dose adjustments - this is a common source of medication errors 4
- Do not use zanamivir in patients with underlying airway disease - risk of bronchospasm is significant 10
The evidence strongly supports oseltamivir as first-line therapy based on extensive clinical trial data, established safety profile, and availability of multiple formulations including oral suspension for patients unable to swallow capsules 2, 1.